In this inaugural episode of the Ophthalmology Times ® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance ...
Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.
4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback